FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094337557> ?p ?o ?g. }

• W2094337557 endingPage "20" @default.
• W2094337557 startingPage "11" @default.
• W2094337557 abstract "Purpose A retrospective study was performed to correlate the expression of epidermal growth factor receptor (EGFR) with treatment outcome in advanced stage nasopharyngeal carcinoma (NPC). Methods and materials The study population comprised 54 of 92 patients with American Joint Committee on Cancer Stage III-IV NPC with sufficient pretreatment tumor biopsy specimens for study. Immunohistochemical staining was performed to evaluate the extent and intensity of EGFR expression. All patients were treated by induction chemotherapy with two to three cycles of cisplatin 60 mg/m2 and epirubicin 110 mg/m2 every 3 weeks followed by radiotherapy. The median follow-up time was 52 months for all patients and 99 months for surviving patients. Results EGFR expression was present in 89% of cases. EGFR intensity was negative in 11%, weak in 43%, moderate in 13%, and strong in 33%. The EGFR extent was <5% in 15%, ≥5% but <25% in 13%, and ≥25% in 72%. No correlation was found between EGFR expression and T stage, N stage, stage group, nodal size, gender, and age. No statistically significant differences in chemotherapy response rates were found in patients with different EGFR intensity and extent. EGFR extent ≥25% was associated with a significantly poorer treatment outcome. The 5-year disease-specific survival, relapse-free survival, locoregional relapse-free, and distant metastasis-free rate in patients with EGFR extent ≥25% was 48%, 36%, 60%, and 55%, respectively. The corresponding rates in patients with EGFR extent <25% were 86%, 80%, 93%, and 86%. The differences were all statistically significant, except for distant metastasis. No statistically significant differences in relapse-free and disease-specific survival rates were found among patients with differing EGFR intensity. In multivariate analysis, EGFR extent was the only independent factor that predicted for disease relapse, locoregional failure, and cancer death. Conclusion Our study results showed that EGFR expression was common in advanced stage NPC, and the expression did not correlate with tumor or nodal stage. Correlative analysis showed that EGFR extent was a strong, independent prognostic factor that determined locoregional control, relapse-free survival, and disease-specific survival in Stage III-IV NPC treated with induction chemotherapy and radiotherapy. Our findings suggest that EGFR expression status can identify a subgroup of patients within advanced stage disease that will have a poor outcome after induction chemotherapy and radiotherapy. Whether this patient subgroup will benefit from an alternate treatment strategy and anti-EGFR–targeted treatment requires additional studies." @default.
• W2094337557 created "2016-06-24" @default.
• W2094337557 creator A5034880731 @default.
• W2094337557 creator A5051945465 @default.
• W2094337557 creator A5077220457 @default.
• W2094337557 creator A5085830513 @default.
• W2094337557 date "2004-05-01" @default.
• W2094337557 modified "2023-10-16" @default.
• W2094337557 title "Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy" @default.
• W2094337557 cites W182988086 @default.
• W2094337557 cites W1838340609 @default.
• W2094337557 cites W1902822116 @default.
• W2094337557 cites W1916546429 @default.
• W2094337557 cites W1971016039 @default.
• W2094337557 cites W1993490224 @default.
• W2094337557 cites W1993891852 @default.
• W2094337557 cites W1995992733 @default.
• W2094337557 cites W2005204942 @default.
• W2094337557 cites W2009334489 @default.
• W2094337557 cites W2010174111 @default.
• W2094337557 cites W2014401523 @default.
• W2094337557 cites W2020583055 @default.
• W2094337557 cites W2020600496 @default.
• W2094337557 cites W2036363901 @default.
• W2094337557 cites W2048578230 @default.
• W2094337557 cites W2062057316 @default.
• W2094337557 cites W2064047613 @default.
• W2094337557 cites W2069457615 @default.
• W2094337557 cites W2084803897 @default.
• W2094337557 cites W2120623522 @default.
• W2094337557 cites W2125919881 @default.
• W2094337557 cites W2151645021 @default.
• W2094337557 cites W4249287287 @default.
• W2094337557 doi "https://doi.org/10.1016/j.ijrobp.2003.10.038" @default.
• W2094337557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15093894" @default.
• W2094337557 hasPublicationYear "2004" @default.
• W2094337557 type Work @default.
• W2094337557 sameAs 2094337557 @default.
• W2094337557 citedByCount "182" @default.
• W2094337557 countsByYear W20943375572012 @default.
• W2094337557 countsByYear W20943375572013 @default.
• W2094337557 countsByYear W20943375572014 @default.
• W2094337557 countsByYear W20943375572015 @default.
• W2094337557 countsByYear W20943375572016 @default.
• W2094337557 countsByYear W20943375572017 @default.
• W2094337557 countsByYear W20943375572018 @default.
• W2094337557 countsByYear W20943375572019 @default.
• W2094337557 countsByYear W20943375572020 @default.
• W2094337557 countsByYear W20943375572021 @default.
• W2094337557 countsByYear W20943375572022 @default.
• W2094337557 countsByYear W20943375572023 @default.
• W2094337557 crossrefType "journal-article" @default.
• W2094337557 hasAuthorship W2094337557A5034880731 @default.
• W2094337557 hasAuthorship W2094337557A5051945465 @default.
• W2094337557 hasAuthorship W2094337557A5077220457 @default.
• W2094337557 hasAuthorship W2094337557A5085830513 @default.
• W2094337557 hasConcept C121608353 @default.
• W2094337557 hasConcept C126322002 @default.
• W2094337557 hasConcept C143998085 @default.
• W2094337557 hasConcept C146357865 @default.
• W2094337557 hasConcept C151730666 @default.
• W2094337557 hasConcept C204232928 @default.
• W2094337557 hasConcept C2775934546 @default.
• W2094337557 hasConcept C2776611710 @default.
• W2094337557 hasConcept C2776694085 @default.
• W2094337557 hasConcept C2776755627 @default.
• W2094337557 hasConcept C2778239845 @default.
• W2094337557 hasConcept C2778997737 @default.
• W2094337557 hasConcept C2779438470 @default.
• W2094337557 hasConcept C2780835546 @default.
• W2094337557 hasConcept C2908647359 @default.
• W2094337557 hasConcept C509974204 @default.
• W2094337557 hasConcept C71924100 @default.
• W2094337557 hasConcept C86803240 @default.
• W2094337557 hasConcept C99454951 @default.
• W2094337557 hasConceptScore W2094337557C121608353 @default.
• W2094337557 hasConceptScore W2094337557C126322002 @default.
• W2094337557 hasConceptScore W2094337557C143998085 @default.
• W2094337557 hasConceptScore W2094337557C146357865 @default.
• W2094337557 hasConceptScore W2094337557C151730666 @default.
• W2094337557 hasConceptScore W2094337557C204232928 @default.
• W2094337557 hasConceptScore W2094337557C2775934546 @default.
• W2094337557 hasConceptScore W2094337557C2776611710 @default.
• W2094337557 hasConceptScore W2094337557C2776694085 @default.
• W2094337557 hasConceptScore W2094337557C2776755627 @default.
• W2094337557 hasConceptScore W2094337557C2778239845 @default.
• W2094337557 hasConceptScore W2094337557C2778997737 @default.
• W2094337557 hasConceptScore W2094337557C2779438470 @default.
• W2094337557 hasConceptScore W2094337557C2780835546 @default.
• W2094337557 hasConceptScore W2094337557C2908647359 @default.
• W2094337557 hasConceptScore W2094337557C509974204 @default.
• W2094337557 hasConceptScore W2094337557C71924100 @default.
• W2094337557 hasConceptScore W2094337557C86803240 @default.
• W2094337557 hasConceptScore W2094337557C99454951 @default.
• W2094337557 hasIssue "1" @default.
• W2094337557 hasLocation W20943375571 @default.
• W2094337557 hasLocation W20943375572 @default.
• W2094337557 hasOpenAccess W2094337557 @default.

• next